Investment report on Catalyst Pharmaceutical Partners announces an investment report featuring Catalyst Pharmaceutical Partners Inc. (Nasdaq:CPRX). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

CPRX is trading above its upper Bollinger Band. Relative to recent price action, the stock is currently overextended and due for either a pause or retracement.

Catalyst Pharmaceutical Partners Inc. (CPRX) is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2009, the Company had two products in development. As of December 31, 2009, the Company was evaluating its product candidate, CPP-109 (its version of vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction. As of December 31, 2009, the Company was in the early stages of developing CPP-115, another GABA aminotransferase inhibitor. CPP-115, like vigabatrin (CPP-109), is a GABA-AT inhibitor. It is developed for both epilepsy (specifically, complex partial seizures and West Syndrome) and drug addiction (cocaine addition). 

Message Board Search for CPRX:

In the report, the analyst notes:

"CPRX recently announced its financial results for the three-month period ended March 31, 2010. The Company reported a net loss of $1,045,043, or $0.06 per basic and diluted share, compared to a net loss of $3,031,201, or $0.22 per basic and diluted share, for the same period in 2009.

"CPRX recently announced that the European Patent Office (EPO) granted to Brookhaven Science Associates/Brookhaven National Laboratory (Brookhaven) a European patent for the use of vigabatrin for the prevention of addiction to opioids (e.g., oxycodone, hydrocodone) used in pain management."

To read the entire report, visit:



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Brain activity patterns during sleep shed light on the neurobiology behind 22q11.2 Deletion Syndrome